Tuesday, July 22, 2014 4:15:57 AM
"How about what the status of the Diwan sale of there(sic) lab to NNVC?"
The first line of the invitation:
"As you know, NanoViricides, Inc (www.nanoviricides.com) has built Connecticut's first and only nanomedicines' clinical product manufacturing facility in Shelton, CT."
No mention of Inno-haven or any indication in the text that it is anything but Nanoviricide's building.
"We are planning the Grand Opening ceremony of our biotech manufacturing facility in Shelton, CT on Monday, July 21 2014 from Noon to 3pm."
You would think from that email that Nanoviricides built it and that Nanoviricdes owns it. I guess some would argue that it doesn't matter, that it wouldn't matter to the email recipients who probably already knew that neither of those things is true and that ownership of the building wasn't one of the grand opening day issues to be discussed so they could freely describe it incorrectly. Just like the patents, management apparently feels free to describe properties as "Nanoviricides'" or "ours" when they actually belong to someone else. Doesn't matter.
The first line of the invitation:
"As you know, NanoViricides, Inc (www.nanoviricides.com) has built Connecticut's first and only nanomedicines' clinical product manufacturing facility in Shelton, CT."
No mention of Inno-haven or any indication in the text that it is anything but Nanoviricide's building.
"We are planning the Grand Opening ceremony of our biotech manufacturing facility in Shelton, CT on Monday, July 21 2014 from Noon to 3pm."
You would think from that email that Nanoviricides built it and that Nanoviricdes owns it. I guess some would argue that it doesn't matter, that it wouldn't matter to the email recipients who probably already knew that neither of those things is true and that ownership of the building wasn't one of the grand opening day issues to be discussed so they could freely describe it incorrectly. Just like the patents, management apparently feels free to describe properties as "Nanoviricides'" or "ours" when they actually belong to someone else. Doesn't matter.
"I ated the purple berries"
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
